American Journal of Epidemiology Vol. 150, No. 8: 861-868
Copyright © 1999 by The Johns Hopkins University School of Hygiene and Public Health
other |
Risk of Breast Cancer According to Use of Antidepressants, Phenothizaines, and Anthistamines
1Slone Epidemiology Unit, Boston University School of Medicine Brookline, MA
2Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine Philadelphia, PA
3Department of Epidemiology and Preventive Medicine, The University of Maryland School of Medicine Baltimore, MD
4Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center New York, NY
Reprint requests to Judith Parsells Kelly, Slone Epidemiology Unit, 1371 Beacon Street, Brookline, MA 02446.
In laboratory studies, some antidepressants caused increased growth of mamary tumors. The relation of use of these drugs to the development of breast cancer was examined in a hospital-based case-control study. Information, including lifetime medication history, was collected by interview from 5,814 women with primary breast cancer diagnosed within the previous years, 5,095 women with primary malignancies of other sites, and 5,814 women with other conditions. Relative risks were estimated by using unconditional multiple logistic regression for regular use (
4 days per week for 4 week begining 1 year before admission) of antidepressants and structurally similar drugs. With reference to never use of each drug, relative risks were statistically compatible with 1.0 for selective serotonin reuptake inhibitors (SSRI), tricyclics, other antidepressants, phenothiazines, and antihistamines; results were very similar using both control groups. There were no significant increases in risk for any category of regular use, stratified according to cumulative duration of use or time interval since the most recent use or for any individual drug within the broader classes. However, the estimate for regular SSRI use in the previous year, 1.8, was of borderline statistical signficance (95% confidence interval: 1.0, 3.3) The findings do not support an overall association between the use of antidepressants, phenothiazines, or antihistamines and breast cancer. However, the results for SSRIs are not entirely reassuring. Am J Epidemiol 1999;150:861–8.
antidepressive agents; second-generation; antidepressive agents; tricyclic; breast neoplasms; case-control studies; histamine H1 antagonists; phenothiazines; serotonin uptake inhibitors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Stebbing, T. Powles, S. Mandalia, M. Nelson, B. Gazzard, and M. Bower Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV J. Clin. Oncol., May 10, 2008; 26(14): 2305 - 2310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Coogan, J. R. Palmer, B. L. Strom, and L. Rosenberg Use of Selective Serotonin Reuptake Inhibitors and the Risk of Breast Cancer Am. J. Epidemiol., November 1, 2005; 162(9): 835 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Turner, Y. Chen, D. Krewski, P. Ghadirian, M. J. Thun, and E. E. Calle Cancer Mortality among US Men and Women with Asthma and Hay Fever Am. J. Epidemiol., August 1, 2005; 162(3): 212 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Ellman and C. R Sunstein Hormesis, the precautionary principle, and legal regulation Human and Experimental Toxicology, December 1, 2004; 23(12): 601 - 611. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Steingart, M. Cotterchio, N. Kreiger, and M. Sloan Antidepressant medication use and breast cancer risk: a case-control study Int. J. Epidemiol., December 1, 2003; 32(6): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Leffondre, M. Abrahamowicz, J. Siemiatycki, and B. Rachet Modeling Smoking History: A Comparison of Different Approaches Am. J. Epidemiol., November 1, 2002; 156(9): 813 - 823. [Abstract] [Full Text] [PDF]
|
|